Emergent Announces Initiation of a Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed – Indolent Lymphoma
ROCKVILLE, Md., Aug 17, 2011 –
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 1b/2 study (16011) of TRU-016 in combination with rituximab and bendamustine for patients with relapsed indolent non-Hodgkin’s B-cell lymphomas, including follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma. TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical(TM) protein therapeutic in development for [...]
In: Chief Medical Officer, Clinical trial, Emergent Bioslutions, Fuad El-Hibri, Healthcare · Tagged with: Fuad El-Hibri, Health, Lymphoma, National Cancer Institute, Non-Hodgkin lymphoma
Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares
CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS) Fuad El-hibri sells 15,000 shares of EBS on 08/11/2009 at an average price of $16.78 a share.
EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops manufactures and commercializes vaccines and therapeutics that assist the body\’s [...]
In: Chief Executive Officer, Emergent Bioslutions, Fuad, Fuad El-Hibri, Shareholder, United States, Washington D.C · Tagged with: Anthrax, Anthrax vaccines, Emergent BioSolutions, Health, Infectious disease, Public health, U.S. Food and Drug Administration, Vaccine
Emergent BioSolutions moves forward with typhoid vaccine
Emergent BioSolutions is on the path to finding gold with its typhoid vaccine following positive results in a Phase II trial.
The Maryland-based biopharmaceutical company is developing a single-dose oral drinkable typhoid vaccine aimed to take on Crucell’s three to four dose oral formulation and Sanofi’s injectable formulation. The global travellers market was worth $130m (€92m) [...]
In: Chief Executive Officer, Clinical trial, Emergent Bioslutions, Fuad, Fuad El-Hibri, United States · Tagged with: Clinical trial, Conditions and Diseases, Crucell, Health, Immune system, Infectious disease, Sanofi-Aventis, Vaccination
EMERGENT BIOSOLUTIONS ANNOUNCES RESULTS FROM ANNUAL MEETING OF STOCKHOLDERS
ROCKVILLE, MD, June 14, 2007—Emergent BioSolutions Inc. (NYSE: EBS), a biopharmaceutical company, announced today the results of the company’s 2007 annual meeting of stockholders, which took place today at the Hyatt Regency Bethesda at 10:00 am Eastern.
There were present, in person or represented by proxy, the holders of more than a majority of the shares [...]
In: Uncategorized · Tagged with: Anthrax, Anthrax vaccines, Business, Company, Emergent BioSolutions, Health, Infectious disease, US Food and Drug Administration
STATEMENT BY FUAD EL-HIBRI, EMERGENT BIOSOLUTIONS CHAIRMAN AND CHIEF EXECUTIVE OFFICER, ON THE PASSING OF ADMIRAL WILLIAM CROWE, JR., FORMER BOARD MEMBER.
ROCKVILLE, MD, October 19, 2007— Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions, issued the following statement on the passing of Admiral William Crowe, Jr., who served on the company’s Board of Directors from 1998-2005.
“I was deeply saddened to learn of the passing of my dear friend and former colleague, the honorable Admiral [...]
In: Uncategorized · Tagged with: Anthrax vaccines, Board of directors, Chief executive officer, Emergent BioSolutions, Health, Infectious disease, United States, US Food and Drug Administration